Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Articles published by VALNEVA

< Previous 1 2 3 Next >
Valneva Provides Update Following European Medicines Agency Announcement on Use of IXCHIQ® in Elderly
From VALNEVA
Via GlobeNewswire
Valneva Reports First Quarter 2025 Financial Results and Provides Corporate Updates
From VALNEVA
Via GlobeNewswire
Valneva Provides Update on Recommendation for Use of Its Chikungunya Vaccine by French Authorities
From VALNEVA
Via GlobeNewswire
Valneva Provides Update on ACIP Recommendation for its Chikungunya Vaccine IXCHIQ® Among U.S. Travelers
From VALNEVA
Via GlobeNewswire
Valneva to Participate in Multiple Events at the 25th World Vaccine Congress, including a Presentation on its Chikungunya Vaccine IXCHIQ®
From VALNEVA
Via GlobeNewswire
Valneva Receives First Marketing Authorization for IXCHIQ® in a Chikungunya Endemic Country
From VALNEVA
Via GlobeNewswire
Valneva and LimmaTech Announce First Vaccination in Phase 2 Infant Study of Tetravalent Shigella Vaccine Candidate S4V2
From VALNEVA
Via GlobeNewswire
Valneva’s Chikungunya Vaccine IXCHIQ® Now Authorized in EU for Adolescents Aged 12 and Above
From VALNEVA
Via GlobeNewswire
Valneva Submits Adolescent Label Extension Application for its Chikungunya Vaccine, IXCHIQ®, to UK MHRA
From VALNEVA
Via GlobeNewswire
Valneva Renews its Sales Agreement in connection with its Existing At-the-Market (ATM) Program
From VALNEVA
Via GlobeNewswire
Valneva Announces Filing of 2024 Universal Registration Document and US Form 20-F
From VALNEVA
Via GlobeNewswire
Valneva Responds to French Government’s Call for Vaccine Supply of IXCHIQ® against Chikungunya Outbreak in La Réunion
From VALNEVA
Via GlobeNewswire
Valneva Reports Full Year 2024 Results and Provides Business Updates and Outlook
From VALNEVA
Via GlobeNewswire
Valneva to Present at Upcoming TD Cowen and Van Lanschot Kempen Healthcare Investor Conferences
From VALNEVA
Via GlobeNewswire
Valneva Receives EMA’s Positive CHMP Opinion for Adolescent Label Extension for Chikungunya Vaccine IXCHIQ®
From VALNEVA
Via GlobeNewswire
Valneva Reports Preliminary Unaudited 2024 Revenue and Cash and Provides 2025 Outlook
From VALNEVA
Via GlobeNewswire
Valneva Receives Marketing Authorization in the UK for the World’s First Chikungunya Vaccine, IXCHIQ®
From VALNEVA
Via GlobeNewswire
Valneva Announces New IXIARO® Supply Contract with the U.S. Government Worth a Minimum of $32.8 Million
From VALNEVA
Via GlobeNewswire
Valneva Reports Positive Phase 2 Results in Children for its Chikungunya Vaccine and Announces Phase 3 Dose Decision
From VALNEVA
Via GlobeNewswire
Valneva Reports High Sustained Immune Response in Adolescents One Year After Single Vaccination with its Chikungunya Vaccine
From VALNEVA
Via GlobeNewswire
Valneva to Meet with Investors during the J.P. Morgan Healthcare Conference
From VALNEVA
Via GlobeNewswire
Valneva Successfully Expands Access to Asia for its Chikungunya Vaccine with Serum Institute of India
From VALNEVA
Via GlobeNewswire
Valneva Announces Peer-Reviewed Publication on the Global Health and Economic Burden of Chikungunya in The British Medical Journal
From VALNEVA
Via GlobeNewswire
Valneva Reports Positive Three-Year Antibody Persistence Data for its Single-Shot Chikungunya Vaccine IXCHIQ®
From VALNEVA
Via GlobeNewswire
Valneva Submits Label Extension Application for its Chikungunya Vaccine, IXCHIQ®, to the U.S. FDA
From VALNEVA
Via GlobeNewswire
Valneva and LimmaTech Announce First Vaccination in Phase 2b Human Challenge Study of Tetravalent Shigella Vaccine Candidate S4V2
From VALNEVA
Via GlobeNewswire
Valneva to Present and Hold Investor Meetings at Upcoming U.S. and European Healthcare Conferences
From VALNEVA
Via GlobeNewswire
Valneva Reports Nine-Month 2024 Financial Results and Provides Corporate Updates
From VALNEVA
Via GlobeNewswire
Valneva to Present on Chikungunya at Several Leading Scientific Conferences
From VALNEVA
Via GlobeNewswire
Valneva and LimmaTech Awarded FDA Fast Track Designation for Tetravalent Shigella Vaccine Candidate S4V
From VALNEVA
Via GlobeNewswire
< Previous 1 2 3 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.